drugset / Trial / NCT04061044

A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert

NCT04061044

Phase 3 Completed 40 enrolled Ocular Therapeutix, Inc.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the long term safety of repeat dose OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension.

Timeline

Start
2018-07-10
Primary completion
2020-02-10
Completion
2020-09-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Travoprost Other / unclassified 0.32 mg Other

Indications